An Update on Hypertrophic Cardiomyopathy
This article will provide a contemporary perspective of HCM, including potential treatment modalities and how its risk is currently stratified. Aspects of this condition that present particular challenges for the insurance underwriter will also be described.
Note: This article begins on page 2.
Hypertrophic Cardiomyopathy vs Athletic Heart Syndrome
In life insurance underwriting, it is important to recognize the differences between hypertrophic cardiomyopathy (HCM) and the benign heart enlargement of an athlete.